triphenylphosphine chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: triphenylphosphine chloride
• 英文别名: chloro(triphenyl)-λ5-phosphane
• 化学式: C₁₈H₁₆ClP
• 分子量: 298.752
• InChiKey: AAHIAAMUDBLHHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.87
• 重原子数：
  20.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

反应信息

• 作为反应物：
  描述：

  triphenylphosphine chloride 在 硫二甘醇 作用下， 生成 [bis(trifluoromethanesulfonyl)imidate](triphenylphosphine)gold(I)
  参考文献：
  名称：

  金 (I) 催化从 γ-酰氧基炔基酮形成呋喃。

  摘要：

  在 70 摄氏度的二氯乙烷中，使用 2.5 mol% 的三氟甲磺酰亚胺（三苯基膦）金 (I) 作为催化剂，各种 γ-酰氧基炔基酮被有效地转化为高度取代的呋喃。

  DOI：

  10.3762/bjoc.9.206

文献信息

• Diphenylacetylene compound, process for preparing the same and liquid
  申请人：Sumitomo Chemical Company, Limited

  公开号：US05658489A1

  公开（公告）日：1997-08-19

  A diphenylacetylene compound of the formula [1]: ##STR1## wherein R is a C.sub.1 -C.sub.12 alkyl group, a C.sub.2 -C.sub.12 alkenyl group or a C.sub.2 -C.sub.16 alkoxyalkyl group; X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are independently from each other a --CH-- group, a --CF-- group or a nitrogen atom; A is a hydrogen atom, a fluorine atom, a trifluoromethyl group, a trifluoromethoxy group, a cyano group, a 4-R.sup.1 -(cycloalkyl) group, 4-R.sup.1 -(cycloalkenyl) group or a R.sup.1 --(O).sub.m group in which R.sup.1 is a C.sub.1 -C.sub.12 alkyl group, a C.sub.2 -C.sub.12 alkenyl group or a C.sub.2 -C.sub.12 alkynyl group; and m is 0 or 1, which has an excellent anisotropy of refractive index and a low viscosity and is useful as a component of a liquid crystal composition.

  一种二苯基炔化合物，其化学式为[1]: ##STR1## 其中，R为C1-C12烷基、C2-C12烯基或C2-C16氧烷基；X1、X2、X3、X4、Y1、Y2、Y3和Y4各自独立为--CH--基团、--CF--基团或氮原子；A为氢原子、氟原子、三氟甲基、三氟甲氧基、氰基、4-R1-(环烷基)基团、4-R1-(环烯基)基团或R1--(O)m基团，其中R1为C1-C12烷基、C2-C12烯基或C2-C12炔基；m为0或1，具有优异的折射率各向异性和低粘度，可用作液晶组合物的组分。
• New CRTH2 Antagonists
  申请人：Almirall, S.A.

  公开号：EP2526945A1

  公开（公告）日：2012-11-28

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

  本发明涉及一种式(I)的化合物，以及制备这种化合物的方法，以及它们在治疗通过CRTh2拮抗活性可改善的病理状况或疾病中的应用。
• [EN] METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE MÉTALLO-BÊTA-LACTAMASE ET LEURS MÉTHODES D'UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2019018186A1

  公开（公告）日：2019-01-24

  The present invention relates to metallo-β-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

  本发明涉及具有以下结构的金属β-内酰胺酶抑制剂化合物的药物学可接受的盐，其中Z、RA、X1、X2和R1如本文所定义。本发明还涉及包含本发明的金属β-内酰胺酶抑制剂化合物或其药学上可接受的盐以及药学上可接受的载体的组合物，可选地与β-内酰胺类抗生素和/或β-内酰胺酶抑制剂结合。该发明还涉及治疗细菌感染的方法，包括向患者投予本发明化合物的治疗有效量，结合治疗有效量的一种或多种β-内酰胺类抗生素，可选地结合一种或多种β-内酰胺酶抑制剂化合物。本发明的化合物在克服抗生素耐药性的方法中具有用处。
• PHENYLPROPIONATE COMPOUND, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF
  申请人：SUZHOU PHARMAVAN CO., LTD

  公开号：US20200331842A1

  公开（公告）日：2020-10-22

  Provided in the present invention are a phenylpropionate compound, a preparation method for same, and applications. The phenylpropionate compound has the structure as represented by formula I. The phenylpropionate compound of the present invention, a pharmaceutically acceptable salt, a solvate, a prodrug, and a tautomer or stereochemical isomer or pharmaceutical composition of the compound provide improved anti-inflammatory and antiplatelet effects and, at the same time, provide an extended time window for treatment, are free of obvious side effects, safe and effective, applicable in an antithrombus, anti-inflammatory, and cerebral stroke treating medicament, and have broad application prospects.

  本发明提供了一种苯丙酸酯化合物及其制备方法和应用。该苯丙酸酯化合物的结构如化学式I所示。本发明的苯丙酸酯化合物、药用可接受的盐、溶剂合物、前药、互变异构体或立体化学异构体或该化合物的药物组合物提供了改进的抗炎和抗血小板效果，并且同时提供了治疗的延长时间窗口，无明显副作用，安全有效，在抗凝血、抗炎和治疗脑卒中药物中适用，并具有广泛的应用前景。
• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE SPHINGOSINE-1-PHOSPHATE
  申请人：EXELIXIS INC

  公开号：WO2010045580A1

  公开（公告）日：2010-04-22

  This disclosure relates to sphingosine-1 -phosphate (SlP) receptor antagonists, compositions comprising the SlP receptor antagonists and methods for using and processes for making the SlP receptor antagonists. In particularly, this disclosure relates to sphingosine-1 -phosphate 1 (SlPl) receptor antagonists, compositions comprising the SlPl receptor antagonist and methods for using the SlPl receptor antagonist, such as in the treatment of cancer, and processes for making the SlPl receptor antagonists.

  这项披露涉及神经酰胺-1-磷酸(S1P)受体拮抗剂，包括该S1P受体拮抗剂的组合物以及使用和制备该S1P受体拮抗剂的方法。特别是，这项披露涉及神经酰胺-1-磷酸1(S1P1)受体拮抗剂，包括该S1P1受体拮抗剂的组合物以及使用该S1P1受体拮抗剂的方法，例如在癌症治疗中，并且包括制备该S1P1受体拮抗剂的方法。